MP48-18 COMPARISON OF PAROXETINE AND DAPOXETINE, A NOVEL SELECTIVE SEROTONIN REUPTAKE INHIBITOR, IN THE TREATMENT OF PREMATURE EJACULATION

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-surgical1 Apr 2014MP48-18 COMPARISON OF PAROXETINE AND DAPOXETINE, A NOVEL SELECTIVE SEROTONIN REUPTAKE INHIBITOR, IN THE TREATMENT OF PREMATURE EJACULATION Abdulmuttalip Simsek, Omer Sarilar, Sinan Kirecci, Onur Kucuktopcu, Faruk Ozgor, Fatih Akbulut, Erkan Sonmezay, Yalcýn Berberoglu, and Gokhan Gurbuz Abdulmuttalip SimsekAbdulmuttalip Simsek More articles by this author , Omer SarilarOmer Sarilar More articles by this author , Sinan KirecciSinan Kirecci More articles by this author , Onur KucuktopcuOnur Kucuktopcu More articles by this author , Faruk OzgorFaruk Ozgor More articles by this author , Fatih AkbulutFatih Akbulut More articles by this author , Erkan SonmezayErkan Sonmezay More articles by this author , Yalcýn BerberogluYalcýn Berberoglu More articles by this author , and Gokhan GurbuzGokhan Gurbuz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1492AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Dapoxetine is a novel SSRI, which acts by potent inhibition of 5-HT transport. As a short acting SSRI, dapoxetine is probably better suited to use as an on-demand treatment for PE. Few studies have compared the performance of paroxetine and dapoxetine in the treatment of PE. Here we have prospectively compared safety and efficacy of daily paroxetine and dapoxetine (30 and 60 mg doses) in patients with PE. Methods We evaluated 150 patients (between 30 and 36 years-old) suffering from PE and referred to our outpatient clinic between May 2009 and November 2012. All patients were married potent men in stable relationship for at least 6 months and had an uncontrolled ejaculation within 1 min of vaginal intromission, with no obvious organic cause for PE Patients were divided into three equal groups of 50 patients. Group 1 patients received 30 mg dapoxetine 1-3 hours before planned intercourse. Group 2 patients received 60 mg dapoxetine 1-3 hours before planned intercourse and group 3 patients received 20 mg paroxetine once a day for a month. All patients followed up for 1 month, beginning after initiation of treatment. Results The average age of all the patients was 33.1 ± 3.2 yr and the mean baseline IELT was 44.9 ± 25.1 sec. There was no difference between groups in terms of age (p=0.18), body mass index (p=0.13), duration of marriage (p=0.20) or baseline IELT scores (p=0.87). The IELT increase from baseline to post-treatment was 117% in the 30 mg dapoxetine group (p<0.01), 170% in the 60 mg dapoxetine group (p<0.01), and 117% in the paroxetine group (p<0.01). The improvement of baseline IELT scores were similar for the 30 mg dapoxetine and paroxetine groups (p>0.05), whereas the improvement of IELT of 60 mg dapoxetine group was better than both the 30 mg dapoxetine (p<0.05) and paroxetine group (p<0.01) (Table 1). Conclusions On demand dapoxetine is a novel effective treatment modality for PE. Although a lower dose of dapoxetine (30 mg) does not outperform the currently used paroxetine treatment, 60 mg dapoxetine 1-3 hours before planned intercourse produces a greater increase in IELT for men with PE, compared to paroxetine. We propose that in cases of severe PE (e.g., IELT less than 30 sec), 60 mg dapoxetine should be given directly. Table 1. IELT score before and after treatment with Dapoxetine and paroxetine in premature ejaculation patients Dapoxetine 30 mg Dapoxetine 60 mg Paroxetine 20 mg Before After p Before After p Before After p IELT ((Seconds) 46,1±23,2 100,2±24,5 a 0,001 43,5±20,6 118,2±40,8 b 0,001 45,2±31,6 98,4±26,3 c 0,001 Values are expressed as mean ± S.D. for each group. IELT: Intravaginal ejaculatory latency time, There was no statistical difference among groups concerning baseline IELT score (p=0.87), a (Dapoxetin 30 mg) vs b ( dapoxetine 60 mg), p<0.05, a vs c ( paroxetine 20 mg), p>0.05, b vs c , p<0.01 © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e534 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Abdulmuttalip Simsek More articles by this author Omer Sarilar More articles by this author Sinan Kirecci More articles by this author Onur Kucuktopcu More articles by this author Faruk Ozgor More articles by this author Fatih Akbulut More articles by this author Erkan Sonmezay More articles by this author Yalcýn Berberoglu More articles by this author Gokhan Gurbuz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...